Rating Rationale
September 04, 2024 | Mumbai
Medicamen Biotech Limited
Ratings reaffirmed at 'CRISIL BBB-/Stable/CRISIL A3'
 
Rating Action
Total Bank Loan Facilities RatedRs.42 Crore
Long Term RatingCRISIL BBB-/Stable (Reaffirmed)
Short Term RatingCRISIL A3 (Reaffirmed)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its 'CRISIL BBB-/Stable/CRISIL A3' ratings on the bank loan facilities of Medicamen Biotech Ltd (MBL; part of the Medicamen group).

 

The ratings continue to reflect the strong track record of the company in the pharmaceutical industry and its healthy financial risk profile. These strengths are partially offset by the modest scale of operations and large working capital requirement.

Analytical approach

CRISIL Ratings has combined the business and financial risk profiles of MBL and its subsidiary, Medicamen Life Sciences Pvt Ltd. These entities, collectively referred to as the Medicamen group, are in the same business and have common management and operational and financial linkages.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

  • Strong track record in the pharmaceutical industry: The promoters have experience of around three decades in the pharmaceuticals industry, and have a diversified clientele comprising the government sector and other customers across India and Africa. Operating income was around Rs 180.4 crore in fiscal 2024. Though clients from Africa contribute around 70% to the sales, MBL is also planning to start sales in European countries and the USA over the medium term, which will support the business risk profile. Furthermore, commercial production of oncology products started from January 2022 onwards, and the company supplies to the domestic market. After approval from the United States Food and Drug Administration, it will also supply to other emerging markets.

 

  • Healthy financial risk profile: Gearing and total outside liabilities to adjusted networth ratio were strong at around 0.17 time and around 0.48 time, respectively, and networth large at around Rs 173 crore as on March 31, 2024. Debt protection metrics were also robust, with interest coverage and net cash accrual to adjusted debt (NCAAD) ratios of around 6.18 times and around 0.52 time, respectively, for fiscal 2024. Financial risk profile is expected to remain healthy over the medium term with networth of above Rs 193 crore, gearing of 0.09 time, and interest coverage and NCAAD ratios of 7 times and above 1 time, respectively. This will be supported by absence of any major debt-funded capital expenditure (capex) and steady accretion to reserve, along with minimal dividend payout of 10%.

 

Weaknesses:

  • Modest scale of operations: Scale of operations is moderate as reflected in operating income of around Rs 179 crore in fiscal 2024, showing a growth of around 28%. Operating margin declined from 18.35% in fiscal 2023 to 13.1% in fiscal 2024 on account of breakeven yet to be achieved for the oncology segment. Margin will be 14-15% as the company expects to achieve breakeven in fiscal 2025. MBL is planning to add new customers in the oncology and non-oncology segments over the medium term. Sustained offtake from the oncology segment, leading to improvement in the overall business risk profile, will remain monitorable.

 

  • Large working capital requirement: Gross current assets (GCAs) were high at around 357 days as on March 31, 2024, due to stretched receivables of 103 days (despite improving from 160 days previous fiscal). This is because while the company gives credit of 21-25 days to domestic clients, payment from ROW (Rest of the World) takes 50-60 days to come, depending on shipment. Export recovery is also delayed due to lengthy invoicing and limited ship availability, causing long waits for shipments to Africa. Payments are usually backed by letter of credit, or in advance in case of exports. Large credit of 120-140 days extended by suppliers (active pharmaceutical ingredient manufacturers) partly eases pressure on the working capital cycle. Prudent working capital management amid increasing scale of operations will be closely monitored. The GCAs are expected to be 320-340 days over the medium term.

Liquidity: Adequate

Bank limit utilisation averaged 47.17% for the 12 months through August 2024. Cash accrual of around Rs 15.9 crore was sufficient to meet debt obligation of around Rs 1.15 crore in fiscal 2024. Cash accrual is expected to remain above Rs 19 crore in fiscal 2025  along with annual debt obligation of Rs 1.25 crore for same fiscal.. The company has no debt obligation from fiscal 2026, which means net cash accrual will cushion liquidity. Dividend payout is estimated to be around 10% of paid-up capital.

Outlook: Stable

The company will continue to benefit from its strong track record in the pharmaceutical industry.

Rating sensitivity factors

Upwards factors:

  • Growth in revenue to over Rs 200 crore and sustenance of operating margin at 15-16%, leading to higher-than-expected net cash accrual
  • Prudent working capital cycle strengthening financial risk profile

 

Downwards factors:

  • Decline in revenue by over 20% and steep fall in operating margin leading to lower cash accrual
  • Any substantial, debt-funded capex or further stretch in working capital cycle impacting financial risk profile and liquidity

About the company

MBL, incorporated in 1993, manufactures pharmaceutical formulations for the overseas and domestic markets. Formulations are based on betalactum and non-betalactum drugs. The company is listed on the Bombay Stock Exchange (BSE). In November 2015, Shivalik Rasayan Ltd, another BSE-listed company, along with five persons acting in concert, had acquired 52% in MBL; Shivalik Rasayan Ltd currently has 41.6% holding in MBL. MBL has manufacturing facilities in Bhiwadi (Rajasthan) and Haridwar (Uttarakhand).

About the group

OPAL Pharmaceuticals Pty Ltd-Australia is not operational. Medicamen Life Sciences Pvt Ltd was incorporated on August 12, 2022, to market pharmaceutical products in the domestic market.

Key financial indicators:

As on / for the period ended March 31

Unit

2024

2023

Operating income

Rs crore

179.3

140.8

Reported profit after tax (PAT)

Rs crore

9.49

14.73

PAT margin

%

5.34

10.45

Adjusted debt/adjusted networth

Times

0.15

0.15

Interest coverage

Times

5.59

7.90

Any other information: Not Applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN Name of the
instrument
Date of
Allotment
Coupon
Rate (%)
Maturity
Date
Issue size
(Rs. Crore)
Complexity
Level
Rating assigned
with outlook
NA  Bank Guarantee  NA  NA  NA  1.5 NA  CRISIL A3 
NA  Cash Credit  NA  NA  NA  23 NA  CRISIL BBB-/Stable 
NA  Composite Working Capital Limit  NA  NA  NA  10.5 NA  CRISIL BBB-/Stable 
NA  Letter of Credit  NA  NA  NA  7 NA  CRISIL A3 

Annexure – List of entities consolidated

Names of entities consolidated

Extent of consolidation

Rationale for consolidation

Medicamen Biotech Ltd

Full consolidation

Common management and business and financial fungibility

Medicamen Life Sciences Pvt Ltd

Full consolidation

Common management and business and financial fungibility

Annexure - Rating History for last 3 Years
  Current 2024 (History) 2023  2022  2021  Start of 2021
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 33.5 CRISIL BBB-/Stable   -- 07-06-23 CRISIL BBB-/Stable 29-03-22 CRISIL BBB-/Stable 11-01-21 CRISIL BBB-/Stable / CRISIL A3 CRISIL BBB-/Stable
Non-Fund Based Facilities ST 8.5 CRISIL A3   -- 07-06-23 CRISIL A3 29-03-22 CRISIL A3 11-01-21 CRISIL A3 CRISIL A3
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Bank Guarantee 1.5 IndusInd Bank Limited CRISIL A3
Cash Credit 23 IndusInd Bank Limited CRISIL BBB-/Stable
Composite Working Capital Limit 10.5 Citibank N. A. CRISIL BBB-/Stable
Letter of Credit 7 IndusInd Bank Limited CRISIL A3
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Nitin Kansal
Director
CRISIL Ratings Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Smriti Singh
Team Leader
CRISIL Ratings Limited
B:+91 124 672 2000
smriti.singh@crisil.com


Sejal Arora
Management Trainee
CRISIL Ratings Limited
B:+91 124 672 2000
Sejal.Arora@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') provided by CRISIL Ratings Limited ('CRISIL Ratings'). For the avoidance of doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for use only within the jurisdiction of India. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings provision or intention to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

The report is a statement of opinion as on the date it is expressed, and it is not intended to and does not constitute investment advice within meaning of any laws or regulations (including US laws and regulations). The report is not an offer to sell or an offer to purchase or subscribe to any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way.

CRISIL Ratings and its associates do not act as a fiduciary. The report is based on the information believed to be reliable as of the date it is published, CRISIL Ratings does not perform an audit or undertake due diligence or independent verification of any information it receives and/or relies on for preparation of the report. THE REPORT IS PROVIDED ON “AS IS” BASIS. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, CRISIL RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE. In no event shall CRISIL Ratings, its associates, third-party providers, as well as their directors, officers, shareholders, employees or agents be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

The report is confidential information of CRISIL Ratings and CRISIL Ratings reserves all rights, titles and interest in the rating report. The report shall not be altered, disseminated, distributed, redistributed, licensed, sub-licensed, sold, assigned or published any content thereof or offer access to any third party without prior written consent of CRISIL Ratings.

CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains or its associates. Ratings are subject to revision or withdrawal at any time by CRISIL Ratings. CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For more detail, please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the Securities and Exchange Board of India regulations (and other applicable regulations, if any), are made available on its websites, www.crisilratings.com and https://www.ratingsanalytica.com (free of charge). CRISIL Ratings shall not have the obligation to update the information in the CRISIL Ratings report following its publication although CRISIL Ratings may disseminate its opinion and/or analysis. Reports with more detail and additional information may be available for subscription at a fee.  Rating criteria by CRISIL Ratings are available on the CRISIL Ratings website, www.crisilratings.com. For the latest rating information on any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisilratings.com/en/home/our-business/ratings/credit-ratings-scale.html